Trial Comparing Outcomes With Merocel Packing or Thrombin-JMI for Anterior Epistaxis
NCT ID: NCT00814333
Last Updated: 2016-01-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
1 participants
INTERVENTIONAL
2008-12-31
2011-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia
NCT01408732
Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)
NCT02638012
Management of Persistent Epistaxis Using Floseal Hemostatic Matrix
NCT02488135
Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
NCT02106520
Microporous Polysaccharide Hemospheres Epistaxis
NCT02466464
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Thrombin-JMI
Thrombin-JMI
5,000 IU, to nasal mucosa via syringe spray applicator
2
Merocel pack
Merocel pack
8 cm pack, inserted within the affected side between the septum and inferior turbinate via bayonet forceps
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Thrombin-JMI
5,000 IU, to nasal mucosa via syringe spray applicator
Merocel pack
8 cm pack, inserted within the affected side between the septum and inferior turbinate via bayonet forceps
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with bleeding disorders
* Known pregnant women or women that think they may be pregnant
* Patients with a know presence of antibodies to bovine thrombin preparations
* Patients that currently have or are known to have a history of systemic skin condition or rash such as eczema or psoriasis
* Patients found to have posterior epistaxis
* Patients requiring a surrogate for medical decisions
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer
INDUSTRY
University of Kansas Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Keith Sale, MD
Associate Professor & Vice Chairman, Otolaryngology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Keith Sale, MD
Role: PRINCIPAL_INVESTIGATOR
University of Kansas Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Kansas Medical Center
Kansas City, Kansas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11564
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.